GALAXI 1: Continued subcutaneous Tremfya benefits IV induction non-responders with Crohn's healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.
TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.